The U.S. government has bought at least 312 million doses of squalene adjuvants from Novartis (MF59) and from GSK (ASO3), according to a report by
Squalene has not been approved by the FDA for use in a vaccine, and manufacturers have not even obtained FDA approval for Phase I clinical trials in
the U.S., the first step toward approval of any new drug, vaccine or adjuvant.
Also, the clinical trials to test the safety of the “swine flu” vaccine being conducted by NIAID will be on only two candidate vaccines that do
not have the adjuvant squalene – and that even though the actual “swine flu” vaccine to be given to people of the USA will have squalene.
The squalene adjuvant unfolds its lethal effect in combination with huge doses of live virus injected into a body whose immune system has already been
weakened. That is precisely the effect of the step-by-step process on how to develop a killer vaccination outlined in the two WHO memos from 1972
discovered by Patrick Jordan.
The existence of a US government stockpile of at least 312 million doses of squalene adjuvants ready to be injected into people will spark fears that
the “swine flu” mass vaccination programme is actually a covert act of biowarfare and the “swine flu” pandemic is being hyped to allow forced
vaccinations with this dangerous substance allowing a radical depopulation.
For more information on just why these “swine flu” vaccine with squalene adjuvants are the most dangerous vaccines ever, visit Dr Rebecca
Carley’s website, www.drcarley.com.
Dr Carley is a court qualified medical expert on vaccine-induced diseases.
Here is the report on adjuvants by Newborg:
Swine Flu Scare: It’s All about The Adjuvant!
August 5, 2009The U. S. government has paid pharmaceutical companies $7.9 billion* since 2004 to develop the capacity to mass vaccine the entire U.S.
population by 2011. Under the perceived threat of H1N1, these plans have been accelerated to include the use of a non FDA approved chemical adjuvant
suspected of causing Gulf War Syndrome, circumventing the FDA approval process for this potentially life threatening chemical.
In 2005, the Department of Health and Human Services (HHS) published a plan with two specific goals that relate to vaccines. The first goal was to
have in place by 2011 domestic production capacity sufficient to supply vaccine to the entire U.S. population within six months of the onset of a
pandemic. The second goal was to stockpile enough doses of vaccine to inoculate 20 million people as soon as possible after the onset of a
As of September 15, 2008, HHS had yet to determine how best to build and develop the capacity to create the hundreds of millions of doses necessary
for such an ambitious undertaking. Three options were identified which could possibly achieve the stated goal by 2011:
Continue to fund and expand funding for the egg-based vaccine antigen production currently utilized in the production of seasonal flu vaccine (viruses
are grown in hens’ eggs). Toward this end, HHS has budgeted $600 million to offer capital subsidies to manufacturers to build egg-based production
facilities in addition to $176 million already awarded.
Continue to fund and expand funding for cell-based vaccine antigen production (for example, viruses grown in the kidneys of dogs) widely used to
manufacture vaccine against polio, chicken pox, measles, mumps, and rubella. To date, HHS has obligated $1.3 billion to promote the development of new
cell-based influenza vaccines.
Fund next generation vaccine manufacturing, based on the use of recombinant-DNA technology. Recombinant vaccines are made by splicing antigen
producing genes into the DNA of another organism (pigs, monkeys, birds, insects, etc.) The modified organisms then reproduce to provide bulk
quantities of antigen. Recombinant techniques are already in use to make vaccines against hepatitis B and human papillomavirus.
All three scenarios had major drawbacks.